Mircera (methoxy polyethylene glycol-epoetin beta) / CSL Behring, Roche  >>  Phase 4
Welcome,         Profile    Billing    Logout  

2 Trials

   Remove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mircera (methoxy polyethylene glycol-epoetin beta) / Roche, CSL Behring
2009-011497-15: PILOT CLINICAL TRIAL WITH MIRCERA (methoxy polyethylene glycol-epoetin beta) IN DIALYSIS UNIT OF A.O. SAN GIOVANNI BATTISTA DI TORINO

Ongoing
4
21
Europe
MIRCERA*IV SC FL 200MCG 1ML, MIRCERA*IV SC FL 200MCG 1ML
AZIENDA SANITARIA OSPEDALIERA \"S. GIOVANNI BATTISTA DI TORINO\"
End stage renal patients in hemodialysis or peritoneal dialysis treatment
 
 
ROQ-IT, NCT05951192: A Prospective Interventional Study Assessing the Clinical and Operational Effectiveness of Transitioning From Mircera to Daprodustat for the Treatment of Anemia in End Stage Kidney Disease

Completed
4
161
US
Daprodustat, JESDUVROQ
USRC Kidney Research, GlaxoSmithKline
Anemia, Renal Insufficiency, Chronic, Renal Anemia
02/24
02/24

Download Options